Overcoming challenges in gammaretroviral vector development and manufacturing

Scroll Down

Rapid expansion in biotechnology platforms and advancement in genetic editing technologies have driven a surge in the use of viral vectors for cell and gene therapies (C&GTs). Offering the ability to carry a large cassette and integrate genes of interest into the host cell’s genome, gammaretroviruses are becoming an increasingly popular choice for C&GTs.

However, navigating the various challenges associated with gammaretrovirus production that can arise during plasmid design, pseudotyping, upstream development, and downstream processing is no simple task. This is further exacerbated by the fact that many manufacturers have pivoted their expertise towards lentivirus production, making it difficult to find expert support.

Offering unparalleled expertise in gammaretroviral vector development and manufacturing, Genezen can help to ensure the success of your project at all stages and navigate possible hurdles.

In our gammaretrovirus development and manufacturing whitepaper, you will learn about the key challenges and considerations, including:

  • Project-specific selection of viral vectors
  • Pseudotyping gammaretrovirus
  • Transient transfection vs stable producer cell lines
  • Sterile filtration challenges
  • Analytical testing capability requirements

Download our gammaretrovirus development and manufacturing whitepaper by completing the form to the right.

You may also be interested in...

ARM A-Cell: New guidance incorporates quality…

Lentiviruses are an essential tool for many cell and gene therapies...

Read more

3 trends in lentivirus development and…

The growth of the cell and gene therapy (C&GT) space, and...

Read more

A trend towards gammaretrovirus in cell…

What’s driving the trending preference for gammaretroviral vectors in C&GT? As...

Read more

Molecule to Market Podcast: Ray Kaczmarek

On a recent episode of the Molecule to Market podcast, Genezen’s...

Read more